Dr. Mark Andrew Gromski, MD

Dr. Gromski practices at IU Health Methodist Hospital in Indianapolis, Indiana, part of Indiana University Health.

Dr. Gromski's NPI, 1255625679, was assigned on June 2, 2011. Dr. Gromski holds Indiana license 01073629A.

Dr. Gromski's primary practice is IU Health Methodist Hospital, at 1701 N Senate Blvd, Indianapolis, IN 46202 in Marion County. The practice phone is (317) 962-2000.

Dr. Gromski's primary practice is IU Health Methodist Hospital in Indianapolis, Indiana, part of Indiana University Health. The medical group on file is IU Health Medical Group. Dmand AI also links Dr. Gromski to 1 more behavioral health center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gromski practices, 2 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Gromski's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Dr. Gromski's licenses on file in 2 states: Indiana and Massachusetts.

CMS data shows 319 Medicare services from Dr. Gromski across 9 procedure codes in 2024, for 203 Medicare patients. Medicare paid $28,683 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 203 Medicare patients who saw Dr. Gromski in 2024. The largest group is 65 to 74, with 94 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 1.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gromski's median patient age at 59, with 53% women.

In 2024, Dr. Gromski wrote 158 Medicare Part D claims for 79 patients. 89% of them were for generic drugs. CMS names the drug for 119 of them, across 6 drugs with 11 or more claims each, at $71,859 in total drug cost. In 2023, CMS named 66 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Gromski for performance year 2024, reported through an alternative payment model (APM). Dr. Gromski accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 265 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Gromski, more than 94% of the clinicians it reports for that procedure.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 79 papers to Dr. Gromski, published from 2011 to 2025. 2019 was the busiest year, with 8. The most frequent topics are Cholangiopancreatography, Endoscopic Retrograde, Swine and Pancreatic Ducts. Dr. Gromski has published most often in Gastrointest Endosc. Dr. Gromski's most frequent co-authors are Evan L. Fogel, MD, Jeffrey James Easler, MD and Glen A. Lehman, MD.

Dmand AI links Dr. Gromski to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Obesity, Pancreatitis, Acute Necrotizing and Overnutrition.

CMS Open Payments shows 204 general payments to Dr. Gromski from 11 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 65% of the total. Boston Scientific Corporation paid the most, $109,696.